Understanding bacteremia, bloodstream infection, and blood infection diagnosis, treatment, and clinical documentation is crucial for healthcare professionals. This resource provides information on bacteremia symptoms, causes, ICD-10 codes, medical coding guidelines, and best practices for accurate clinical documentation and patient care. Learn about blood culture testing, antibiotic treatment options, and sepsis management related to bacteremia. Explore relevant information for physicians, nurses, and other medical professionals involved in the diagnosis and management of bacteremia and related bloodstream infections.
Presence of bacteria in the bloodstream.
Fever, chills, rapid heart rate, low blood pressure, confusion.
Hospital-acquired infections, intravenous lines, surgical procedures.
Complete code families applicable to R78.81
| Description | When to use |
|---|---|
| Bacteria in the bloodstream. | Use for positive blood cultures or strong clinical suspicion with systemic signs. |
| Systemic inflammatory response to infection. | Use for suspected infection with 2+ SIRS criteria (fever, tachycardia, tachypnea, leukocytosis). |
| Infection originating from a localized site. | Document the source of infection (e.g., pneumonia, UTI) and 'with bacteremia' if applicable. |
Confusing bacteremia with sepsis or severe sepsis can lead to inaccurate coding and DRG assignment.
Insufficient documentation to support bacteremia diagnosis may cause coding and billing errors.
Lack of specificity regarding the causative organism impacts coding accuracy and reimbursement.
Verify positive blood culture: organism, source
Review patient's signs/symptoms (fever, chills, hypotension)
Assess risk factors: central lines, immunosuppression, recent surgery
Consider alternative diagnoses: localized infection, drug reaction
Document infection source and antibiotic treatment plan
Patient presents with signs and symptoms suggestive of bacteremia, also known as a bloodstream infection or blood infection. Clinical manifestations include fever, chills, rigors, tachycardia, hypotension, and altered mental status. The patient's medical history includes [relevant comorbidities, e.g., diabetes, indwelling catheter, recent surgery]. Physical examination reveals [relevant findings, e.g., warm skin, flushed appearance, murmur]. Preliminary differential diagnosis includes sepsis, septic shock, and other infectious processes. Blood cultures have been drawn and sent for laboratory analysis to identify the causative organism and determine antibiotic susceptibility. Empiric antibiotic therapy has been initiated with [antibiotic name and dosage] pending culture results. The patient's condition is being closely monitored for signs of clinical deterioration. Further diagnostic workup may include complete blood count (CBC) with differential, procalcitonin, lactate, and imaging studies as clinically indicated. Treatment plan includes intravenous fluids, hemodynamic support, and adjustment of antibiotics based on culture results and clinical response. Patient education provided regarding bacteremia symptoms, treatment, and potential complications. Coding considerations include ICD-10-CM code for bacteremia (B95.6) and appropriate CPT codes for blood cultures and other diagnostic and therapeutic procedures performed. Differential diagnosis considerations for billing and medical necessity documentation include sepsis, severe sepsis, and septic shock, to be documented appropriately if suspected or confirmed.
Empiric antibiotic therapy for suspected gram-negative bacteremia in critically ill adults must cover a broad spectrum of potential pathogens, including resistant organisms like *Pseudomonas aeruginosa* and *Enterobacteriaceae* producing extended-spectrum beta-lactamases (ESBLs) or carbapenemases. Current guidelines, such as those from the Infectious Diseases Society of America (IDSA) and local antibiograms, recommend initial treatment with a combination of a beta-lactam with activity against *Pseudomonas* (e.g., piperacillin-tazobactam, cefepime, meropenem, imipenem-cilastatin) and an aminoglycoside (e.g., gentamicin, tobramycin, amikacin). For patients with risk factors for carbapenem-resistant *Enterobacteriaceae* (CRE), alternative options include ceftazidime-avibactam, meropenem-vaborbactam, or colistin. De-escalation of therapy based on culture results and clinical response is crucial to minimize the emergence of resistance. Consider implementing rapid diagnostic testing, such as PCR or MALDI-TOF, to facilitate prompt identification of the causative pathogen and guide targeted antibiotic therapy. Explore how antimicrobial stewardship programs can optimize antibiotic use in your ICU.
Differentiating true bacteremia from blood culture contamination is a common challenge. Clinicians should consider several factors. True bacteremia is more likely with multiple positive blood cultures, especially if they grow the same organism. The clinical presentation of the patient, including fever, chills, hypotension, and other signs of systemic infection, supports the diagnosis of bacteremia. Common skin contaminants include coagulase-negative staphylococci, *Corynebacterium* species, *Propionibacterium acnes*, and *Bacillus* species. However, these organisms can occasionally cause true infection, especially in immunocompromised patients or those with indwelling medical devices. The time to positivity in blood cultures can also be helpful; rapid growth of pathogens typically suggests true bacteremia. Repeating blood cultures after appropriate skin disinfection helps rule out contamination. Learn more about best practices for blood culture collection and interpretation to improve diagnostic accuracy.
The optimal duration of antibiotic therapy for uncomplicated gram-positive bacteremia depends on several factors, including the causative organism, source of infection, and clinical response. For uncomplicated *Staphylococcus aureus* bacteremia without an indwelling medical device, current guidelines generally recommend 14 days of intravenous antibiotics after the first negative blood culture and documented clinical improvement. For streptococcal bacteremia, shorter courses (7-10 days) may be sufficient if the source is controlled and the patient responds favorably. However, longer durations may be necessary for infections involving prosthetic valves or other implantable devices. Adequate source control, such as removal of infected catheters or drainage of abscesses, is paramount for successful treatment. Consider implementing clinical pathways for bacteremia management to standardize care and improve patient outcomes. Explore how telehealth can be used for monitoring patients receiving outpatient parenteral antibiotic therapy (OPAT).
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.